Nearly 70% of patients showed improvement after treatment with efgartigimod plus rHuPH20 in phase 2 of the largest randomized controlled trial for CIDP to date.
Multiple system atrophy is a rare and fatal neurodegenerative disease, where insoluble inclusions of the protein alpha-synuclein appear in oligodendrocyte cells of the brain.
HyQvia, which combines immunoglobulin with hyaluronidase, is administered subcutaneously by a healthcare professional or the patient or caregiver, after appropriate training.